2.1. International Strategy
Internationalization is recognized as an important means of corporate growth and sustained profit creation among corporate strategies. Due to this importance, many researchers are making efforts to identify the relationship between internationalization and performance [
11]. However, empirical studies of firms’ internationalization and performance show mixed results and fail to produce consistent conclusions [
12]. Some studies have shown a positive relationship between internationalization and performance, but some studies have reported negative relationships, S-curves, U-shapes, and inverted U-shapes [
11,
12,
13,
14,
15,
16,
17,
18].
Generally, previous researches on internationalization and performance relationship support a positive relationship between the two [
3,
11]. International strategies offer benefits such as economies of scale, economies of scope, learning opportunities, and the sharing of core competencies and as firms expand into international markets to exploit more resources, this leads to higher performance [
13].
However, some studies show a negative relationship between internationalization strategy and performance of a firm. For instance, Denis et al. [
14] found a negative relationship between internationalization and performance and argued that the costs of internationalization strategy outweigh the benefits. Lu and Beamish [
17] investigated the effects of internationalization on small and medium-sized enterprises (SMEs) performance using a sample of 164 Japanese SMEs and found a U-shape relationship. The U-shape relationship of internationalization strategy and performance showed the inherent costs associated with internationalization, especially at the early stage of internationalization strategy. Lu and Beamish [
17] found that internationalization strategy and performance had an S-curve relationship which showed that in the early stage of internationalization, performance decreases as internationalization progresses, but performance decreases when the internationalization level is high. Also, Hitt et al. [
16] found the inverted U-shape association between internationalization and performance.
All those studies regarding internationalization and performance showed the existence of cost associated with internationalization strategy (e.g., coordination cost, governance cost, information processing cost, and the liability of foreignness) and benefits of internationalization strategy. In addition, the results of inconsistent previous studies imply that the impact of internationalization on performance is influenced by a variety of situational factors, and it depends on the industry to which the firm belongs, and the core strategies that the firms take [
13,
15].
Since the impact of internationalization strategy on firm performance occurs after time passes, the benefits of internationalization may not be directly reflected in the performance of the firm if the performance is measured only by short-term performance. Therefore, it is important to measure and analyze long-term performance such as sustainable earnings to grasp the effect of internationalization strategy on performance more accurately.
2.2. R&D Intensity
Many firms are investing in R&D activities more and more because the technology revolution and innovation is a key factor in enhancing competitiveness and long-term sustainable growth in this era [
6,
19]. The competitive advantage of biotech firms lies in a deep knowledge base of biochemical processes and innovativeness [
20].
The biotech industry is a high-tech industry where technology is particularly important, and continuous R&D spending is very important [
21]. However, innovation activities such as R&D investments have characteristics such as being long-term, high-risk, and difficult to predict future profitability [
6,
11].
In this aspect, considerable prior research has investigated the implications of R&D intensity on the firms’ performance. For instance, previous literature generally supports a positive association between R&D intensity and firm performance in sales growth, market value or firm value [
3,
6,
22]. However, previous empirical results on R&D intensity and firm performance have been mixed with other research studies that have found negative results. For instance, Vithessonthi and Racela [
5] tested R&D intensity on firm performance using non-financial firms listed on the US stock exchange and showed that there is a negative relationship between R&D intensity and operating performance.
Furthermore, though other research has explored the ways in which firm performance is affected by internationalization and R&D, the results have been inconsistent, suggesting a complicated relationship [
5]. Such a relationship exists between internationalization strategy and R&D because the direct and combined effects of R&D and internationalization is context-specific [
5], which raises the need to examine the biotech industry in Korea.
2.3. International Strategy, R&D of Biotech Industry
Prior studies on the biotech firms’ internationalization strategies generally focused on the following topics. Research by Bialek-Jaworska and Gabryelczyk [
23] reported on the business model determinants and associated features of biotech spin-off activity, which are crucial factors in implementing the internationalization strategy. The study documented that not only international cooperation in research projects and partnering but also international experience in the management board and tacit knowledge take a facilitating role in the business model for the commercialization of biotech spin-off research outcomes. Another stream of research examined the internationalization of R&D activity. They reported that the internal R&D determinants encouraging a firm to invest in R&D overseas is owning R&D performing affiliates abroad [
24]. Additionally, the findings found that a higher share of R&D internationalization is associated with a more structured organization of R&D at homes, such as performing R&D in dedicated laboratories and the propensity to outsource R&D to foreign non-affiliated partners. Kale [
25] demonstrated its collaboration with multinational corporation (MNC), which revealed internationalization in the form of acquisitions of foreign firms and has formed the core foundation of the technology upgrade strategy for Indian firms. Veilleux and Roy [
26] explored through strategic alliances how corporate and scientific advisory boards participate in the internationalization of biotechnology firms. Using semi-structured interviews and secondary data from 22 biotech firms, this study showed the nature of this external strategic advice and examined their impact on the internationalization of the firms. Rahko [
27] investigated how innovations change when European firms start to internationalize their R&D activities and the results showed that the start of R&D internationalization further increased firms’ innovative output.
The above studies provide important insights into the inter-relationship between internationalization related strategy and R&D of biotech firms, however, they have not examined the direct relationship between sustained performance and internationalization strategy, and the moderating effect of R&D strategy.
Though some research has been conducted on the performance implications of an internationalization strategy, few studies have focused on the internationalization strategies of biotech firms in particular and the relationship between those strategies and sustainable earnings. In a rare and important study on this subject, Qian and Li [
3] examined the effects that niche operation, market awareness, innovator positioning, and internationalization had on small and medium-sized biotech firms. The authors found that, among those small and medium-sized biotech firms, internationalization was positively related to profitability. However, that study was limited in that it analyzed only small and medium-sized biotech firms and did not consider sustainability. Our study expands upon previous research by employing a new measure of sustainable earnings, namely, the persistence of earnings. While other measures of profitability represent a specific moment in time, the persistence of earnings is a flow variable measured over time, making it more representative of sustainability and less vulnerable to manipulation.
2.4. Hypothesis Development
Many researchers argue that if a firm has a competitive advantage, it will have a positive impact on the performance of the firm if it is internationalized [
5,
13,
28,
29]. By pursuing internationalization strategy firms can enjoy the following benefits.
First, when a firm enters the international market, the firm can enjoy economies of scale by lowering production costs because production and sales volume increase [
30,
31]. Internationalization plays an important role in ensuring the competitiveness of a firm as a means of achieving economies of scale in functional areas such as marketing costs and R&D expenses, as well as reducing the cost of firms due to economies of scale [
32].
Second, firms can maximize the location advantage and benefit from the difference in factor markets by placing value chain activities around the world [
11]. The difference between different factor markets in different countries is providing firms with opportunities to improve overall profitability by restructuring their operations to lower costs [
33].
Third, if there is a limit to the growth of the domestic market, the effect of risk diversification can be anticipated from the perspective of the firm as it can enjoy sustained growth through building a foundation in the international market [
34].
In short, internationalization strategy provides the opportunity for exploring a new or niche market, spreading fixed costs of R&D or marketing, and exploiting location-specific advantages which all lead firms to increase sales and competitiveness [
29].
All these arguments support the view that there is a positive and linear relationship between internationalization strategies and corporate performance. However, we argue that the relationship between international strategy and sustainable earnings for biotech firms is somewhat different than for manufacturing firms. In contrast to a positive relationship between international strategy and sustainable earnings, which has been the premise and evidence in prior researches, we argue that the relationship is a negative relationship for biotech firms.
Internationalization of firms is exposed to the cultural and institutional environment of various countries, and due to the liability of foreignness, there is an additional cost to dealing with the foreign market environment [
11]. While this logic applies to non-biotech firms, the cost of dealing with internationalization, which is essentially required for biotech firms, will be higher than that of non-biotech firms. For biotech firms, the key strategy for innovation is the R&D investment strategy [
35], and the firm’s main value chain activities will be focused on R&D strategies. Therefore, high levels of complexity resulting from pursuing an internationalization strategy may worsen performance [
5].
In this sense, the increasing level of internationalization of biotech firms implies that transaction costs, governance costs, and information processing demands increase [
13]. Owing to the complexity of internationalization strategy operations, a high level of internationalization of a biotech firm can have a negative impact on sustainable earnings.
Also, firms generally have limited resources to implement strategies, it is not easy to pursue all strategies at the same time, and trade-off exists between them [
5]. For implementing the internationalization strategy, a firm has to make a considerable level of investment, the higher the commitment to internationalization strategy, the lower the possibility of putting that resource into a R&D capacity. This could have a negative impact on sustainable earnings for biotech firms.
Hypothesis 1 (H1). The level of internationalization of a biotech firm has a negative effect on sustainable earnings.
The second hypothesis expands the first hypothesis and analyzes the moderating effect of R&D intensity on the relationship between internationalization strategy and sustainable earnings. While internationalization strategy has a negative effect on sustainable earnings for a biotech firm, we contend that if a biotech firm’s R&D intensity is high, the sustainable earnings will improve.
Previous research has shown that when firms are internationalized, they are exposed to learning opportunities for innovation, which ultimately has a positive impact on performance [
36] and by receiving information and feedback from customers and partners in foreign markets through internationalization, such as exports, companies can apply this knowledge to innovation [
5]. Biotech firms need to sell their products in as many markets as possible in order to distribute their enormous R&D costs across more products, and internationalization strategy is beneficial in this respect [
3] because long-term profitability improvement through market expansion can be expected.
Indeed, as multinational corporations increase their overseas business activities, their corporate value increases [
37] and investors tend to appreciate overseas profits relatively more because their growth potential in overseas markets is larger than the domestic market [
38]. Therefore, it can be expected that biotech firms will have a positive R&D intensity and will adjust their relationship to sustainable earnings if they are internationalized. In fact, corporate value increases as multinational companies increase their overseas business activities [
37], and investors tend to appreciate overseas profits relatively more because their overseas markets are more likely to grow than their domestic counterparts [
38]. Also, because the biotech industry is rapidly shortening its lifecycle, a biotech firm must maximize their sales as quickly as possible by exploiting new products developed overseas [
3].
Many biotech firms have suffered for a long time from sluggish earnings due to large-scale investment in R&D. Still, there is a reason why firms are investing in R&D. This is because the scale of compensation for internationalization through technology exports is enormous. For example, Yuhan, a representative biotech firm in Korea, contracted an exporting contract with Boehringer Riegelheim, a global pharmaceutical company, in 2019. The contract, worth
$870 million, was for a fusion protein technology used to treat non-alcoholic steatohepatitis [
39]. In the past year, Yuhan has completed a total of four new drugs. Through the contract for the candidate material, the export of technology amounted to 3.3 trillion won. Yuhan has continued to invest in the most important R&D investment in the future growth engine in recent years and steadily increasing its R&D investment is a big factor in its success. In other words, while maintaining a high level of R&D investment, it is possible to improve profitability by opening up overseas markets and expanding the market. In fact, innovation capability through R&D investment is a key success factor to succeed in the global market [
11].
Thus, we anticipate that biotech firms pursuing an internationalization strategy with a high level of R&D intensity is positively related to sustainable earnings of a biotech firm.
Hypothesis 2 (H2). R&D intensity positively moderates the effect of the level of the internationalization on a biotech firm’s sustainable earnings.